Meeting
2018 ASCO Annual Meeting
Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study.
Authors
Veerisa Vimolchalao
Division of Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Veerisa Vimolchalao , Siwat Sakdejayont , Ploytuangporn Wongchanapai , Shama Sukprakun , Suleepon Uttamapinan , Nattaya Sintawichai , Nattaya Poovorawan , Sutima Luangdilok , Napa Parinyanitikul , Chanida Vinayanuwattikun , Virote Sriuranpong , Suebpong Tanasanvimon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10019)
DOI
10.1200/JCO.2018.36.15_suppl.10019
Abstract #
10019
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2021 ASCO Annual Meeting
The equivalency study of novel current standard 3-drugs combination regimen (ondansetron, dexamethasone and olanzapine) to netupitant containing regimen for preventing high dose cisplatin induce nausea and vomiting treatment, double blind placebo control trial.
First Author: Chalermchai Lertanansit
Poster
2013 ASCO Annual Meeting
Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
First Author: Paul Joseph Hesketh
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan